Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2014-09-21

FDA Approved: AMLODIPINE BESYLATE — Supplemental Application (Ascend Laboratories, LLC)

View source ↗

Summary

FDA approves Ascend Laboratories' supplemental application for amlodipine besylate (a generic calcium channel blocker) as an additional approved product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amlodipine besylate (amlodipine besylate)

Snippet

SUPPL AP for AMLODIPINE BESYLATE (AMLODIPINE BESYLATE)